Abstract | BACKGROUND: OBJECTIVE: To evaluate the safety and efficacy of CCH for treatment of EFP. MATERIALS AND METHODS: In a randomized, double-blind study, women with moderate or severe EFP of the buttocks or posterolateral thighs (i.e., Clinician Reported Photonumeric Cellulite Severity Scale [CR-PCSS] and Patient Reported Photonumeric Cellulite Severity Scale [PR-PCSS] ratings of 3 to 4, and Hexsel Cellulite Severity Scale score ≤13) received up to 3 treatment sessions (Days 1, 22, and 43) of subcutaneous CCH 0.84 mg or placebo injections. End points included the percentage of 2-level and 1-level composite responders (i.e., had ≥2-level or ≥1-level improvement in CR-PCSS and PR-PCSS) at Day 71. RESULTS: Three hundred seventy-five women (mean age, 46.5 years; 86.4% white) were randomly assigned to CCH (n = 189) or placebo (n = 186). At Day 71, the percentages of 2-level and 1-level composite responders were greater with CCH (10.6% and 44.6%, respectively) versus placebo (1.6% and 17.9%; p < .001 for both). The most common adverse events were injection-site related. CONCLUSION: CCH significantly improved EFP appearance versus placebo; further evaluation of CCH for EFP ( cellulite) is warranted.
|
Authors | Neil S Sadick, Mitchel P Goldman, Genzhou Liu, Neil H Shusterman, Michael P McLane, David Hurley, V Leroy Young |
Journal | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
(Dermatol Surg)
Vol. 45
Issue 8
Pg. 1047-1056
(08 2019)
ISSN: 1524-4725 [Electronic] United States |
PMID | 30829779
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Buttocks
- Cellulite
(drug therapy)
- Double-Blind Method
- Edema
(drug therapy)
- Female
- Humans
- Injections, Intralesional
- Microbial Collagenase
(therapeutic use)
- Middle Aged
- Severity of Illness Index
- Thigh
|